Journal of Reconstructive Urology

.: ORIGINAL RESEARCH
Antikoagülan/Antiagregan İlaç Kullanımının Mesane Kanserinin Primer Tanı Evresine Etkisi: Retrospektif Kesitsel Çalışma
The Effect of Anticoagulant/Antiagregan Drug Usage on the Primary Diagnosis Stage of Bladder Cancer: A Retrospective Cross-sectional Study
Nusret Can ÇİLESİZa , Mustafa Asım AVCIb
aBiruni Üniversitesi Tıp Fakültesi, Üroloji ABD, İstanbul, Türkiye
bGaziosmanpaşa Eğitim ve Araştırma Hastanesi, Üroloji Kliniği, İstanbul, Türkiye
J Reconstr Urol. 2023;13(2):47-52
doi: 10.5336/urology.2023-95961
Article Language: TR
Full Text
ÖZET
 Amaç: Bu çalışmada, makroskobik hematüri sonrası primer mesane kanseri tespit edilen hastalarda antikoagülan ve/veya antiagregan ilaç kullanımının hastalığın teşhisindeki evresine olan etkisini araştırmayı amaçladık. Gereç ve Yöntemler: Çalışma retrospektif olarak makroskobik hematüri gelişimi sonrasında primer mesane kanseri tespit edilen hastalar arasında yapıldı. Hastaların yaş, cinsiyet, sigara kullanımı, Amerikan Anesteziyoloji Derneği skoru kaydedildi. Nonürotelyal mesane kanseri olanlar, pür karsinoma in situ olarak raporlanan olgular, komşu organ invazyonu olarak patolojik tanı alan hastalar dâhil edilmedi. Hastaların tümör sayısı, boyutu, T evresi ve tümör derecesi kaydedildi. Hastaların Avrupa Üroloji Derneği mesane kanseri risk gruplandırması (düşük, orta veya yüksek) kaydedildi. Hastalar antikoagülan ve/veya antiagregan tedavi (AAT) kullanım durumuna göre AAT (+) ve AAT (-) olarak 2 gruba ayrıldı. 'Her iki grubun sosyodemografik ve histopatolojik özellikleri karşılaştırmalı olarak analiz edildi. Bulgular: Çalışmaya retrospektif olarak taranan ve kriterlere uyan 153 hasta dâhil edildi. Hastaların ortalama yaşı 64,69±12,25 idi. Hastalardan 54'ünün (%35,2) AAT (+) ve 99'unun (%64,8) AAT (-) grupta olduğu hesaplandı. Her iki grubun analizinde yaş, cinsiyet, tümör sayısı açısından anlamlı fark olmadığı görüldü (p>0,05). Tümör boyutu <3 cm (%75,9'a karşı %62,6; p=0,091) olan hastaların oranı AAT (+) grubunda daha fazla olsa da anlamlı fark izlenmedi. Kas invaziv hastalık oranı (≥T2) (%17,1'e karşı %3,7; p=0,015) ve yüksek dereceli mesane kanseri oranının (%46,4'e karşı %27,7; p=0,024) AAT (-) grupta istatistiksel anlamlı olarak daha fazla olduğu hesaplandı. Rekürrens risk skorlamasına göre Avrupa Kanser Araştırma ve Tedavi Organizasyonu ≤5 olan (%66,6'ya karşı %45,4; p=0,012) hastaların AAT (+) grupta daha fazla olduğu görüldü. Sonuç: Bu çalışmada, makroskobik hematüri ile tanı alan primer mesane kanserinde AAT kullanımının hastalığın daha düşük evre ve derecede saptanması ile ilişkili olduğu sonucuna varıldı.

Anahtar Kelimeler: Mesane kanseri; makroskobik hematüri; antiagregan ilaçlar; antikoagülan ilaçlar
ABSTRACT
 Objective: We aimed to investigate the effect of anticoagulant and/or anti-aggregant drug use on the stage of diagnosis of the disease in patients with primary bladder cancer after macroscopic hematuria. Material and Methods: The study was conducted retrospectively among patients with primary bladder cancer after the development of macroscopic hematuria. Age, gender, smoking, American Society of Anesthesiology scores of the patients were recorded. Patients with nonurothelial bladder cancer, carcinoma in-situ, and adjacent organ invasion were not included. The tumor number, size, T stage and tumor grade of the patients were recorded. European Association of Urology bladder cancer risk group (low, moderate, or high) were recorded. The patients were divided into two groups as AAT (+) and AAT (-) according to their use of anticoagulant and/or anti-aggregant therapy (AAT). Sociodemographic characteristics, histopathological characteristics of the both groups were analyzed comparatively. Results: A total of 153 patients who were retrospectively screened and met the criteria were included in the study. The mean age of the patients was 64.69±12.25. It was calculated that 54 (35.2%) of the patients were in the AAT (+) and 99 (64.8%) patients were in the AAT (-) group. There was no significant difference in terms of age, gender and tumor number (p>0.05). Although the proportion of patients with tumor size T2) (17.1% vs 3.7%; p=0.015) and high-grade bladder cancer rate (46.4% vs. 27.7%; p=0.024) were calculated to be higher in the AAT (-) group. According to the recurrence risk score, patients with a European Cancer Research and Treatment Organization score of ≤5 (66.6% vs. 45.4%; p=0.012) were found to be more common in the AAT (+) group. Conclusion: It was concluded that the use of AAT provoked the development of macroscopic hematuria and enabled the detection of bladder cancer at an earlier stage.

Keywords: Bladder cancer; macroscopic hematuria; antiaggregant drugs; anticoagulant drugs
REFERENCES:
  1. Witjes JA, Bruins HM, Cathomas R, Compérat EM, Cowan NC, Gakis G, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol. 2021;79(1):82-104. [Crossref]  [PubMed] 
  2. Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005;66(6 Suppl 1):4-34. [Crossref]  [PubMed] 
  3. Anastasiadis A, de Reijke TM. Best practice in the treatment of nonmuscle invasive bladder cancer. Ther Adv Urol. 2012;4(1):13-32. [Crossref]  [PubMed]  [PMC] 
  4. Mi-ana B, Cózar JM, Palou J, Unda Urzaiz M, Medina-Lopez RA, Subirá Ríos J, et al. Bladder cancer in Spain 2011: population based study. J Urol. 2014;191(2):323-8. [Crossref]  [PubMed] 
  5. Hirsh J. Oral anticoagulant drugs. N Engl J Med. 1991;324(26):1865-75. [Crossref]  [PubMed] 
  6. Blankenship JC. Bleeding complications of glycoprotein IIb-IIIa receptor inhibitors. Am Heart J. 1999;138(4 Pt 2):287-96. [Crossref]  [PubMed] 
  7. Avidor Y, Nadu A, Matzkin H. Clinical significance of gross hematuria and its evaluation in patients receiving anticoagulant and aspirin treatment. Urology. 2000;55(1):22-4. [Crossref]  [PubMed] 
  8. Lotan Y, Kamat AM, Porter MP, Robinson VL, Shore N, Jewett M, et al; Bladder Cancer Think Tank; Bladder Cancer Advocacy Network; Society of Urologic Oncology. Key concerns about the current state of bladder cancer: a position paper from the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology. Cancer. 2009;115(18):4096-103. [Crossref]  [PubMed] 
  9. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108. [Crossref]  [PubMed] 
  10. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19(3):666-75. [Crossref]  [PubMed] 
  11. Yafi FA, Aprikian AG, Chin JL, Fradet Y, Izawa J, Estey E, et al. Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience. BJU Int. 2011;108(4):539-45. [Crossref]  [PubMed] 
  12. Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer. 2015;15(1):25-41. [Crossref]  [PubMed] 
  13. Moschini M, Karnes RJ, Suardi N, Bianchi M, Pellucchi F, Rocchini L, et al. Potential effect of antiplatelet and anticoagulant therapy on the timing of the diagnosis of bladder cancer. Clin Genitourin Cancer. 2016;14(3):e245-50. [Crossref]  [PubMed] 
  14. Mariani AJ, Mariani MC, Macchioni C, Stams UK, Hariharan A, Moriera A. The significance of adult hematuria: 1,000 hematuria evaluations including a risk-benefit and cost-effectiveness analysis. J Urol. 1989;141(2):350-5. [Crossref]  [PubMed] 
  15. Khadra MH, Pickard RS, Charlton M, Powell PH, Neal DE. A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol. 2000;163(2):524-7. [Crossref]  [PubMed] 
  16. Sutton JM. Evaluation of hematuria in adults. JAMA. 1990;263(18):2475-80. [Crossref]  [PubMed] 
  17. Keeling D, Baglin T, Tait C, Watson H, Perry D, Baglin C, et al; British Committee for Standards in Haematology. Guidelines on oral anticoagulation with warfarin - fourth edition. Br J Haematol. 2011;154(3):311-24. [Crossref]  [PubMed] 
  18. Serebruany VL, Malinin AI, Eisert RM, Sane DC. Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials. Am J Hematol. 2004;75(1):40-7. [Crossref]  [PubMed] 
  19. Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2009;54(23):2205-41. Erratum in: J Am Coll Cardiol. 2009;54(25):2464. Erratum in: J Am Coll Cardiol. 2010;55(6):612. Dosage error in article text. [PubMed] 
  20. Loewen P, Dahri K. Risk of bleeding with oral anticoagulants: an updated systematic review and performance analysis of clinical prediction rules. Ann Hematol. 2011;90(10):1191-200. [Crossref]  [PubMed] 
  21. Culclasure TF, Bray VJ, Hasbargen JA. The significance of hematuria in the anticoagulated patient. Arch Intern Med. 1994;154(6):649-52. [Crossref]  [PubMed] 
  22. Shinagare AB, Silverman SG, Gershanik EF, Chang SL, Khorasani R. Evaluating hematuria: impact of guideline adherence on urologic cancer diagnosis. Am J Med. 2014;127(7):625-32. [Crossref]  [PubMed] 
  23. Nieder AM, Lotan Y, Nuss GR, Langston JP, Vyas S, Manoharan M, et al. Are patients with hematuria appropriately referred to Urology? A multi-institutional questionnaire based survey. Urol Oncol. 2010;28(5):500-3. [Crossref]  [PubMed] 
  24. Friedlander DF, Resnick MJ, You C, Bassett J, Yarlagadda V, Penson DF, et al. Variation in the intensity of hematuria evaluation: a target for primary care quality improvement. Am J Med. 2014;127(7):633-40.e11. [Crossref]  [PubMed]  [PMC] 

.: Up To Date

.: Process List

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com